When less is more - efficacy with less toxicity at the ED50

被引:29
作者
Dimmitt, Simon [2 ,3 ]
Stampfer, Hans [4 ,5 ]
Martin, Jennifer H. [1 ,6 ]
机构
[1] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2298, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, 3-10 McCourt St, West Leederville 6007, Australia
[3] Australian Community & Hlth Fdn, West Leederville 6007, Australia
[4] Univ Western Australia, Joondalup Hlth Campus, Crawley, WA 6009, Australia
[5] Sir Charles Gairdner Hosp, Perth, WA, Australia
[6] Hunter New England Local Hlth Dist, Dept Med, Newcastle, NSW, Australia
关键词
dose-response; effective dose 50; pharmaceutical marketing; ACUTE CORONARY SYNDROMES; STATIN THERAPY; HEART-DISEASE; MORTALITY; METAANALYSIS; CHOLESTEROL; MORBIDITY;
D O I
10.1111/bcp.13281
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:1365 / 1368
页数:4
相关论文
共 27 条
[1]   Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials [J].
Afilalo, Jonathan ;
Majdan, Agnieska A. ;
Eisenberg, Mark J. .
HEART, 2007, 93 (08) :914-921
[2]   A systematic review of hospitalization resulting from medicine-related problems in adult patients [J].
Al Hamid, Abdullah ;
Ghaleb, Maisoon ;
Aljadhey, Hisham ;
Aslanpour, Zoe .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (02) :202-217
[3]   Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension [J].
Bangalore, Sripal ;
Sawhney, Sabrina ;
Messerli, Franz H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1482-1489
[4]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[5]   Bariatric surgery: A systematic review and meta-analysis [J].
Buchwald, H ;
Avidor, Y ;
Braunwald, E ;
Jensen, MD ;
Pories, W ;
Fahrbach, K ;
Schoelles, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14) :1724-1737
[6]   Aspirin dose for the prevention of cardiovascular disease - A systematic review [J].
Campbell, Charles L. ;
Smyth, Susan ;
Montalescot, Gilles ;
Steinhubl, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :2018-2024
[7]   Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999 [J].
Cross, J ;
Lee, H ;
Westelinck, A ;
Nelson, J ;
Grudzinskas, C ;
Peck, C .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (06) :439-446
[8]  
Dimmitt SB, BR J CLIN PHARM, V78, P1076
[9]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
[10]   Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial [J].
Konstam, Marvin A. ;
Neaton, James D. ;
Dickstein, Kenneth ;
Drexler, Helmut ;
Komajda, Michel ;
Martinez, Felipe A. ;
Riegger, Gunter A. J. ;
Malbecq, William ;
Smith, Ronald D. ;
Guptha, Soneil ;
Poole-Wilson, Philip A. .
LANCET, 2009, 374 (9704) :1840-1848